By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Oncology have been published. According to news reporting from Beijing, People's Republic of China, by NewsRx journalists, research stated, "A somatostatin analog, vapreotide (VAP), can be used as a ligand for targeting drug delivery based on its high affinity to somatostatin receptors (SSTRs), which is overexpressed in many tumor cells. RNA interference plays an important role on downregulation of vascular endothelial growth factor (VEGF), which is important for tumor growth, progression and metastasis."
The news correspondents obtained a quote from the research from Peking University, "To improve tumor therapy efficacy, the vapreotide-modified core-shell type nanoparticles co-encapsulating VEGF targeted siRNA (siVEGF) and paclitaxel (PTX), termed as VAP-PLPC/siRNA NPs, were developed in this study. When targeted via somatostatin receptors to tumor cells, the VAP-PLPC/siRNA NPs could simultaneously delivery siVEGF and PTX into cells and achieve a synergistic inhibition of tumor growth. Interestingly, in vitro cell uptake and gene silencing experiments demonstrated that the targeted VAP-PLPC/siRNA NPs exhibited significant higher intracellular siRNA accumulation and VEGF downregulation in human breast cancer MCF-7 cells, compared to those of the non-targeted PEG-PLPC/siRNA NPs. More importantly, in vivo results further demonstrated that the targeted VAP-PLPC/siRNA NPs had significant stronger drug distribution in tumor tissues and tumor growth inhibition efficacy via receptor-mediated targeting delivery, accompany with an obvious inhibition of neovascularization induced by siVEGF silencing."
According to the news reporters, the research concluded: "These results suggested that the co-delivery of siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles would be a promising approach for tumor targeted therapy."
For more information on this research see: Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles. Biomaterials, 2014;35(18):5028-38. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
Our news journalists report that additional information may be obtained by contacting Q. Feng, State Key Laboratory of Natural and Biomimetic Drugs, School of pharmaceutical sciences, Peking University, Beijing 100191, People's Republic of China. Additional authors for this research include M.Z. Yu, J.C. Wang, W.J. Hou, L.Y. Gao, X.F. Ma, X.W. Pei, Y.J. Niu, X.Y. Liu, C. Qiu, W.H. Pang, L.L. Du and Q. Zhang (see also Oncology).
Keywords for this news article include: Asia, VEGF, Antineoplastics, Pharmaceuticals, Drugs, siRNA, Beijing, Taxoids, Therapy, Genetics, Oncology, Terpenes, Paclitaxel, Hydrocarbons, Nanoparticle, Somatostatin, Breast Cancer, Neuropeptides, Cycloparaffins, Nanotechnology, Women's Health, Protein Kinases, Peptide Hormones, Membrane Proteins, Organic Chemicals.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC